相似文献
1
Matrix heparan sulphate, but not endothelial cell surface heparan sulphate, is degraded by highly metastatic mouse lymphoma cells.
Br J Cancer. 1988 Aug;58(2):186-8. doi: 10.1038/bjc.1988.189.
2
Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines.
Science. 1983 May 6;220(4597):611-3. doi: 10.1126/science.6220468.
3
Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity.
J Cell Biol. 1990 Mar;110(3):767-75. doi: 10.1083/jcb.110.3.767.
4
Specific degradation of subendothelial matrix proteoglycans by brain-metastatic melanoma and brain endothelial cell heparanases.
J Cell Physiol. 1997 Sep;172(3):334-42. doi: 10.1002/(SICI)1097-4652(199709)172:3<334::AID-JCP7>3.0.CO;2-P.
5
Heparan sulphate proteoglycans.
Biochem Soc Trans. 1990 Apr;18(2):207-9. doi: 10.1042/bst0180207.
6
7
Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix.
J Cell Physiol. 1986 Aug;128(2):299-306. doi: 10.1002/jcp.1041280223.
8
Immunoelectron microscopy of endothelial cells in rat incisor suggests that most basement membrane components are produced by young cells, whereas heparan sulfate proteoglycan is produced by both young and old cells.
J Histochem Cytochem. 1988 Jul;36(7):763-73. doi: 10.1177/36.7.2968396.
9
Heparan sulfate-binding peptide promotes the deposition of proteoglycans in the extracellular matrix.
J Cell Biochem. 1997 Jun 15;65(4):574-90. doi: 10.1002/(sici)1097-4644(19970615)65:4<574::aid-jcb12>3.0.co;2-c.
10
Loss of heparan sulphate proteoglycan and retinal microinfarcts in diabetes mellitus.
Diabetologia. 1989 Oct;32(10):766. doi: 10.1007/BF00274541.
引用本文的文献
1
Human platelet heparanase: purification, characterization and catalytic activity.
Biochem J. 1998 Mar 15;330 ( Pt 3)(Pt 3):1341-50. doi: 10.1042/bj3301341.
本文引用的文献
1
Clonal analysis of expression of tumor-associated transplantation antigens and of metastatic capacity.
Cancer Immunol Immunother. 1982;13(1):62-8. doi: 10.1007/BF00200203.
2
Metastatic potential severely altered by changes in tumor cell adhesiveness and cell-surface sialylation.
J Exp Med. 1983 Jan 1;157(1):371-6. doi: 10.1084/jem.157.1.371.
3
Glycoconjugates of murine tumor lines with different metastatic capacities. I. Differences in fucose utilization and in glycoprotein patterns.
Int J Cancer. 1984 Apr 15;33(4):503-9. doi: 10.1002/ijc.2910330414.
4
5
6
Selective degradation of basement membrane macromolecules by metastatic melanoma cells.
J Natl Cancer Inst. 1984 Apr;72(4):889-99.
7
Tumor invasion and host extracellular matrix.
Cancer Metastasis Rev. 1983;2(2):129-52. doi: 10.1007/BF00048966.
8
Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines.
Science. 1983 May 6;220(4597):611-3. doi: 10.1126/science.6220468.
9
Different expression of Lyt differentiation antigens and cell surface glycoproteins by a murine T lymphoma line and its highly metastatic variant.
Eur J Immunol. 1982 Apr;12(4):300-7. doi: 10.1002/eji.1830120409.
10
Glycoconjugates of murine tumor lines with different metastatic capacities. II. Diversity of glycolipid composition.
Int J Cancer. 1985 Nov 15;36(5):601-7. doi: 10.1002/ijc.2910360514.
Zotero 插件